The ocular surface · 2025
Predictors of vision-related quality of life in patients treated for filamentous fungal keratitis.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prajna N V, Radhakrishnan N, Lalitha Prajna, Rajaraman Revathi, Abdelrahman Sarah, Arnold Benjamin F, Lietman Thomas M, Rose-Nussbaumer Jennifer, Arboleda Alejandro
Аннотация
PURPOSE: To identify clinical characteristics that predict vision-related quality of life (QoL) in patients with fungal keratitis three months after treatment.
METHODS: Patients with fungal keratitis enrolled in the Cross-Linking Assisted Infection Reduction trial were treated with topical natamycin 5 % or amphotericin 0.15 %, with or without adjuvant corneal cross-linking (CXL). Demographic data, ulcer characteristics, clinical course, and responses to the Indian Visual Function Questionnaire (IND-VFQ) were collected at baseline and follow-up. Logistic regression models were used to assess factors associated with patient-reported vision-related QoL at three months. Analyses included the average IND-VFQ score as well as Rasch-derived subscale scores for vision-specific mobility, activity limitation, psychosocial impact, and visual symptoms.
RESULTS: Of 111 participants enrolled, 86 had complete data at both timepoints. Multivariable models identified baseline IND-VFQ score, scar size, and presence of hypopyon as significant predictors of 3-month IND-VFQ scores. A 1-point change in best spectacle corrected visual acuity is correlated with a 13.4-point change in the opposite direction in average IND-VFQ (P=0.001). Patients with adverse events requiring surgery had lower 3-month IND-VFQ scores than those managed medically (P=0.001). Ulcer characteristics including location, depth, symptom duration, repeat culture positivity, organism type, and fungal genus were not associated with final IND-VFQ scores.
CONCLUSIONS: Vision-related QoL after fungal keratitis is significantly influenced by change in visual acuity, need for surgical intervention, and select baseline factors including scar size, initial IND-VFQ score, and presence of hypopyon. Vision-related QoL did not differ by antifungal treatment or adjuvant CXL use.
METHODS: Patients with fungal keratitis enrolled in the Cross-Linking Assisted Infection Reduction trial were treated with topical natamycin 5 % or amphotericin 0.15 %, with or without adjuvant corneal cross-linking (CXL). Demographic data, ulcer characteristics, clinical course, and responses to the Indian Visual Function Questionnaire (IND-VFQ) were collected at baseline and follow-up. Logistic regression models were used to assess factors associated with patient-reported vision-related QoL at three months. Analyses included the average IND-VFQ score as well as Rasch-derived subscale scores for vision-specific mobility, activity limitation, psychosocial impact, and visual symptoms.
RESULTS: Of 111 participants enrolled, 86 had complete data at both timepoints. Multivariable models identified baseline IND-VFQ score, scar size, and presence of hypopyon as significant predictors of 3-month IND-VFQ scores. A 1-point change in best spectacle corrected visual acuity is correlated with a 13.4-point change in the opposite direction in average IND-VFQ (P=0.001). Patients with adverse events requiring surgery had lower 3-month IND-VFQ scores than those managed medically (P=0.001). Ulcer characteristics including location, depth, symptom duration, repeat culture positivity, organism type, and fungal genus were not associated with final IND-VFQ scores.
CONCLUSIONS: Vision-related QoL after fungal keratitis is significantly influenced by change in visual acuity, need for surgical intervention, and select baseline factors including scar size, initial IND-VFQ score, and presence of hypopyon. Vision-related QoL did not differ by antifungal treatment or adjuvant CXL use.